B7-H3, B7-H4, Foxp3 and IL-2 expression in cervical cancer: Associations with patient outcome and clinical significance

Oncology Reports

Volumn 35, Issue 4, 2016, Pages 2183-2190

  Huang, Chenglin ^a   Zhou, Lei ^a   Chang, Xiaohan ^a   Pang, Xiaoao ^a   Zhang, Huijie ^a   Zhang, Shulan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

B7 H3; B7 H4; Cervical cancer; Co stimulatory molecule; Foxp3; Immunohistochemistry

Indexed keywords

B7 H3 PROTEIN; INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3; TUMOR MARKER; UNCLASSIFIED DRUG; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; B7 ANTIGEN; CD276 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; VTCN1 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CERVICAL CANCER CELL LINE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR VOLUME; UTERINE CERVIX CANCER; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; UPREGULATION; UTERINE CERVIX TUMOR; YOUNG ADULT;

ADULT; AGED; B7 ANTIGENS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; INTERLEUKIN-2; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; UP-REGULATION; UTERINE CERVICAL NEOPLASMS; V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1; YOUNG ADULT;

EID: 84958581717     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4607     Document Type: Article

References (41)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P and Allison JP: B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 104: 19458-19463, 2007.
3. Tsiaousidou A, Lambropoulou M, Chatzitheoklitos E, Tripsianis G, Tsompanidou C, Simopoulos C and Tsaroucha AK: B7H4, HSP27 and DJ-1 molecular markers as prognostic factors in pancreatic cancer. Pancreatology 13: 564-569, 2013.
4. Zhao X, Li DC, Zhu XG, Gan WJ, Li Z, Xiong F, Zhang ZX, Zhang GB, Zhang XG and Zhao H: B7-H3 overexpression in pancreatic cancer promotes tumor progression. Int J Mol Med 31: 283-291, 2013.
5. Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK and Wang X: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53: 143-151, 2006.
6. Schneider T, Hoffmann H, Dienemann H, Schnabel PA, Enk AH, Ring S and Mahnke K: Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J Thorac Oncol 6: 1162-1168, 2011.
7. Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC and Kwon ED: B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival. Proc Natl Acad Sci USA 103: 10391-10396, 2006.
8. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, et al: Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 14: 5150-5157, 2008.
9. Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, Wolfert RL and Kim NW: B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 66: 1570-1575, 2006.
10. Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, et al: Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 23: 1104-1112, 2010.
11. Liu W, Shibata K, Koya Y, Kajiyama H, Senga T, Yamashita M and Kikkawa F: B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients. Mol Clin Oncol 2: 219-225, 2014.
12. Mailloux AW and Young MR: Regulatory T-cell trafficking: From thymic development to tumor-induced immune suppression. Crit Rev Immunol 30: 435-447, 2010.
13. Lu X, Liu J, Li H, Li W, Wang X, Ma J, Tong Q, Wu K and Wang G: Conversion of intratumoral regulatory T cells by human gastric cancer cells is dependent on transforming growth factor-1. J Surg Oncol 104: 571-577, 2011.
14. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR and June CH: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766-4772, 2001.
15. Wang HY and Wang RF: Regulatory T cells and cancer. Curr Opin Immunol 19: 217-223, 2007.
16. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grüssel S, Sipos B, Grützmann R, Pilarsky C, Ungefroren H, Saeger HD, et al: Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67: 8344-8350, 2007.
17. Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, McNally B, Lin L, Zhou P, Zuo T, et al: Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 16: 336-346, 2009.
18. Wang LH, Su L and Wang JT: Correlation between elevated FOXP3 expression and increased lymph node metastasis of gastric cancer. Chin Med J (Engl) 123: 3545-3549, 2010.
19. Zang X, Loke P, Kim J, Murphy K, Waitz R and Allison JP: B7x: A widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA 100: 10388-10392, 2003.
20. Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, Chapoval AI, Flies DB, Bajorath J and Chen L: B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18: 849-861, 2003.
21. Prasad DV, Richards S, Mai XM and Dong C: B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18: 863-873, 2003.
22. Wang X, Wang T, Xu M, Xiao L, Luo Y, Huang W, Zhang Y and Geng W: B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas. Hum Immunol 75: 1203-1209, 2014.
23. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G and Zou W: Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 67: 8900-8905, 2007.
24. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, et al: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203: 871-881, 2006.
25. Galazka K, Opawski M, Windorbska W, Skret-Magierlo J, Koper K, Basta P, Mach P, Dutch-Wicherek M, Mazur A and Wicherek L: The immunohistochemical analysis of antigens such as RCAS1 and B7H4 in the cervical cancer nest and within the fibroblasts and macrophages infiltrating the cancer microenvironment. Am J Reprod Immunol 68: 85-93, 2012.
26. Yamato I, Sho M, Nomi T, Akahori T, Shimada K, Hotta K, Kanehiro H, Konishi N, Yagita H and Nakajima Y: Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 101: 1709-1716, 2009.
27. Arigami T, Narita N, Mizuno R, Nguyen L, Ye X, Chung A, Giuliano AE and Hoon DS: B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg 252: 1044-1051, 2010.
28. Sun TW, Gao Q, Qiu SJ, Zhou J, Wang XY, Yi Y, Shi JY, Xu YF, Shi YH, Song K, et al: B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence. Cancer Immunol Immunother 61: 2171-2182, 2012.
29. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, et al: B7-H3 ligand expression by prostate cancer: A novel marker of prognosis and potential target for therapy. Cancer Res 67: 7893-7900, 2007.
30. Quandt D, Fiedler E, Boettcher D, Marsch WC and Seliger B: B7-h4 expression in human melanoma: Its association with patients' survival and antitumor immune response. Clin Cancer Res 17: 3100-3111, 2011.
31. Boland JM, Kwon ED, Harrington SM, Wampfler JA, Tang H, Yang P and Aubry MC: Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 14: 157-163, 2013.
32. Strauss L, Bergmann C, Szczepanski M, GooDing W, Johnson JT and Whiteside TL: A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13: 4345-4354, 2007.
33. Geng Y, Wang H, Lu C, Li Q, Xu B, Jiang J and Wu C: Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol 20: 273-281, 2015.
34. Luo Q, Zhang S, Wei H, Pang X and Zhang H: Roles of Foxp3 in the occurrence and development of cervical cancer. Int J Clin Exp Pathol 8: 8717-8730, 2015.
35. Chen L: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4: 336-347, 2004.
36. Zang X and Allison JP: The B7 family and cancer therapy: Costimulation and coinhibition. Clin Cancer Res 13: 5271-5279, 2007.
37. Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, Zhu Y, Flies DB, Tamada K and Chen L: Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 171: 4650-4654, 2003.
38. Tringler B, Zhuo S, Pilkington G, Torkko KC, Singh M, Lucia MS, Heinz DE, Papkoff J and Shroyer KR: B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 11: 1842-1848, 2005.
39. Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J and Shroyer KR: B7-H4 overexpression in ovarian tumors. Gynecol Oncol 100: 44-52, 2006.
40. Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A and Shroyer KR: B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol 106: 119-127, 2007.
41. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I and Allison JP: A pilot trial of CTLA-4 blockade with human anti CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13: 1810-1815, 2007.